Structural characterization of N-linked oligosaccharides on monoclonal antibody Nimotuzumab through process development

Biologicals

Volumn 40, Issue 4, 2012, Pages 288-298

  Montesino, Raquel ^a   Calvo, Loany ^b   Vallin, Antonio ^b   Rudd, Pauline M ^c   Harvey, David J ^c   Cremata, José A ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Immunoassay Center Cuba   (Cuba)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

IgG1 monoclonal antibody; N Glycosylation pattern; NS0 murine myeloma cell line

Indexed keywords

ASPARAGINE LINKED OLIGOSACCHARIDE; CIMAHER; GLYCAN; IMMUNOGLOBULIN G; MANNOSE; MONOCLONAL ANTIBODY; N GLYCOLYL SIALIC ACID; NIMOTUZUMAB; SIALIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BATCH PROCESS; CONTROLLED STUDY; DRUG MANUFACTURE; DRUG STRUCTURE; FUCOSYLATION; GLYCOSYLATION; MOUSE; MYELOMA CELL; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; SIALYLATION; STRUCTURE ANALYSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CARBOHYDRATE CONFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; OLIGOSACCHARIDES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

MURINAE;

EID: 84863778190     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.04.005     Document Type: Article

References (41)

1. Krapp S., Mimura Y., Jefferis R., Huber R., Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003, 325:979-989.
2. Shields R.L., Lai J., Keck R.L., O'Connell Y., Hong K., Meng Y.G., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc-RIII and antibody-dependent cellular toxicity. J Biol Chem 2002, 277:26733-26740.
3. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003, 278:3466-3473.
4. Wright A., Morrison S.L. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998, 160:3393-3402.
5. Hodoniczky J., Zheng Y.Z., James D.C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005, 21:1644-1652.
6. Nam J.H., Zhang F., Ermonval M., Linhardt R.J., Sharfstein S.T. The effects of culture conditions on the glycosylation of secreted human placental alkaline phosphatase produced in Chinese hamster ovary cells. Biotechnol Bioeng 2008, 100:1178-1192.
7. Gawlitzek M., Estacio M., Fürch T., Kiss R. Identification of cell culture conditions to control N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO cells. Biotechnol Bioeng 2009, 103:1164-1175.
8. van Berkel P.H.C., Gerritsen J., Perdok G., Valbjørn J., Vink T., van deWinkel J.G.J., et al. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol Prog 2009, 25:244-251.
9. Dinnis D.M., Stansfield S.H., Schlatter S., Smales C.M., Alete D.E., Birch J.R., et al. Functional proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnol Bioeng 2006, 94:830-841.
10. Codamo J., Cheng Hou J.J., Hughes B.S., Gray P.P., Munro T.P. Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1. J Chem Technol Biotechnol 2011, 86:923-934.
11. Hossler P., Khattak S.F., Li Z.J. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 2009, 19:936-949.
12. Jimenez del Val I., Kontoravdi C., Nagy J.M. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog 2010, 26:1505-1527.
13. Gawlitzek M., Valley U., Nimtz M., Wagner R., Conradt H.S. Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions. J Biotechnol 1995, 42:117-131.
14. Scanlan C.N., Burton D.R., Dwek R.A. Making autoantibodies safe. Proc Natl Acad Sci U S A 2008, 105:4081-4082.
15. Schiestl M., Stangler T., Torella C., Čepeljnik T., Toll H., Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011, 29:310-312.
16. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001, 1:118-129.
17. Robinson M., Weiner L., Adams G. Improving monoclonal antibodies for cancer therapy. Drug Dev Res 2004, 61:172-187.
18. Yamashita M., Katakura Y., Shirahata S. Recent advances in the generation of human monoclonal antibody. Cytotechnology 2007, 55:55-60.
19. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
20. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005, 21:11-16.
21. Liu H., Gaza-Bulseco G., Faldu D., Chumsae C., Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci 2008, 97:2426-2447.
22. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008, 9:482-501.
23. Qian J., Liu T., Yang L., Daus A., Crowley R., Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007, 364:8-18.
24. Mateo C., Moreno E., Amour K., Lombardero J., Harris W., Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997, 3:71-81.
25. Bigge J.C., Patel T.P., Bruce J.A., Goulding P.N., Charles S.M., Parekh R.B. Nonselective and efficient fluorescent labeling of glycans using 2-aminobenzamide and anthranilic acid. Anal Biochem 1995, 230:229-238.
26. Guile G.R., Wong S.Y., Dwek R.A. Analytical and preparative separation of anionic oligosaccharides by weak anion exchange high-performance liquid chromatography on an inert polymer column. Anal Biochem 1994, 222:231-235.
27. Guile G.R., Rudd P.M., Wing D.R., Prime S.B., Dwek R.A. A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 1996, 240:210-226.
28. Harvey D.J. Quantitative aspects of the matrix-assisted laser desorption mass spectrometry of complex oligosaccharides. Rapid Commun Mass Spectrom 1993, 7:614-619.
29. Matamoros L.E., Kalume D.E., Calvo L., Fernandez M., Vallin A., Roepstorff P. Characterization of a recombinant monoclonal antibody by mass spectrometry combined with liquid chromatography. J Chromatogr 2001, 752:247-261.
30. Royle L., Radcliffe C.M., Dwek R.A., Rudd P.M. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods in molecular biology 2006, vol. 347:125-144. Humana Press. I. Brockhausen-Schutzbach (Ed.).
31. Harvey D.J., Merry A.H., Royle L., Campbell M.P., Dwek R.A., Rudd P.M. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 2009, 9:3796-3801.
32. Wheeler S.F., Domann P., Harvey D.J. Derivatization of sialic acids for stabilization in matrix-assisted laser desorption/ionization mass spectrometry and concomitant differentiation of α→2-3 and α→2-6 isomers. Rapid Commun Mass Spectrom 2009, 23:303-312.
33. Harvey D.J. Fragmentation of negative ions from carbohydrates: part 1; use of nitrate and other anionic adducts for the production of negative ion electrospray spectra from N-linked carbohydrates. J Am Soc Mass Spectrom 2005, 16:622-630.
34. Harvey D.J. Fragmentation of negative ions from carbohydrates: part 2, fragmentation of high-mannose N-linked glycans. J Am Soc Mass Spectrom 2005, 16:631-646.
35. Harvey D.J. Fragmentation of negative ions from carbohydrates: part 3, fragmentation of hybrid and complex N-linked glycans. J Am Soc Mass Spectrom 2005, 16:647-659.
36. Harvey D.J., Royle L., Radcliffe C.M., Rudd P.M., Dwek R.A. Structural and quantitative analysis of N-linked glycans by MALDI and negative ion nanospray mass spectrometry. Anal Biochem 2008, 376:44-60.
37. Domon B., Costello C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj J 1998, 5:397-409.
38. Sheeley D.M., Merrill B.M., Taylor L.C.E. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal α-linked galactose. Anal Biochem 1997, 47:102-110.
39. Kamoda S., Ishikawa R., Kakehi K. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A 2006, 1133:332-339.
40. Bergwerff A.A., Stroop C.J.M., Murray B., Holtorf A.P., Pluschke G., Oostrum J., et al. Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. Glycoconj J 1995, 12:318-330.
41. Mohan S.B., Chohan S.R., Eade J., Lyddiatt A. Molecular integrity of monoclonal antibodies produced by hybridoma cells in batch culture and in continuous-flow culture with integrated product recovery. Biotechnol Bioeng 1993, 42:974-986.